drugset / Trial / NCT05438875
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
Phase 3
Completed
96 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabBeijing Tongren Hospital · collabNavy General Hospital, Beijing · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A Prospective, Randomized, Open-Label, Multicenter Clinical Trial study to compare the efficacy and safety of ATRA plus eltrombopag compared to eltrombopag monotherapy in the treatment of steroid-resistant/relapsed immune thrombocytopenia (ITP).
Timeline
- Start
- 2022-10-12
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 50 mg | — |
| Subject | Tretinoin | Small molecule | 10 mg | Oral |